Abstract

Razine Sawssane*, Najem Salma, Harrak Soukaina, Lemsanes Siham, Benchekroun Khadija, Sninate Sanae, Lkhoyaali Siham, Boutayeb Saber and Errihani hassane

ABSTRACT

The chronic use of immunosuppressive agents is associated with the long-term risk of a wide variety of malignancies, including Kaposi’s sarcoma (KS), in renal transplant recipients compared with those of the general population. An increased risk of post-transplant KS may be related to HHV-8 infection, and pre-transplantation HHV-8 seropositivity is a risk factor Management of Kaposi’s sarcoma generally includes radiotherapy for focal disease and chemotherapy for systemic disease. In renal transplant patients, The dose reduction or cessation of immunosuppresive drugs is the mainly approach for the treatment. Here we describe a case of 59-year-old woman who developed disseminated Kaposi s sarcoma one year after kidney transplantation, his immunosuppressive therapy was prednisolone 20 mg/day, Tacrolimus (Prograf®) 4 mg/day, and mycophenolate mofetil (MMF) 500 gr/day. The decision was made for monotherapy immunosuppression with 5 mg prednisolone, then Systemic chemotherapy with paclitaxel with good progress under treatment. In renal transplant patients, the dose reduction or cessation of immunosuppressive drugs is the mainly approach for the treatment.